INTRODUCTION
The introduction of biologic medicines for the treatment of rheumatoid arthritis (RA) has resulted in a significant improvement in the clinical and radiographic outcomes among patients with RA over the last 10 years. Evidence has shown that low disease activity (LDA) and even remission in RA is achievable with the combination of biologics and nonbiologic disease-modifying antirheumatic drugs (DMARDs) in a larger proportion than with less aggressive, nonbiologic DMARDs regimens [1] . Comparative efficacy research has been a major area of interest in the last several years so as to allow more direct comparisons between biologics and to establish evidence-based differences or similarities in both efficacy and safety.
This article summarizes recent data from controlled trials on antitumor necrosis factor (TNF) and nonanti-TNF biologics for the treatment of RA. The four key domains to be covered will include efficacy of new therapies (including new formulations), comparative efficacy between approved agents, the possibility of anti-TNF discontinuation, and potential effects on cardiovascular disease (CVD) risk factors and risk of cardiovascular events.
EFFICACY STUDIES FOR ANTITUMOR NECROSIS FACTOR AND NONANTITUMOR NECROSIS FACTOR BIOLOGICS
golimumab was given at weeks 0, 4 and then every 8 weeks for a total of 24 weeks [2] . At week 14, intravenous golimumab showed significant efficacy based on the American College of Rheumatology response (ACR) 20 compared with placebo (59 vs. 25%, P < 0.001) ( Fig. 1) .
A phase III trial of subcutaneous TCZ presented at the 2012 ACR meeting in Washington, DC, showed noninferiority of TCZ 162 mg subcutaneous every week to TCZ 8 mg/kg intravenous every month. The primary outcome was the proportion of patients in each group meeting the ACR20 criteria at week 24 using a 12% noninferiority margin [3] . At week 24, 69.4% [95% confidence interval (CI) 65.5-73.2] of TCZ subcutaneous-treated patients vs. 73.4% (95% CI 69.6-77.1) of TCZ intravenoustreated patients achieved an ACR20 response [3] , which satisfied the noninferiority endpoint. The ACR 50/70 responses were likewise comparable between the subcutaneous and intravenous TCZ, as was safety. Another trial evaluated TCZ 162 mg subcutaneous every 2 weeks (approximating the 4 mg/kg intravenous monthly dose) to placebo subcutaneous and showed that significantly more patients receiving TCZ achieved ACR20 responses at week 24 compared with placebo (60.9 vs. 31.5%), and ACR50 (39.8 vs. 12.3%) and ACR70 responses (19.7 vs. 5.0%) were higher as well [4] .
A phase IIIb trial of certolizumab pegol (CZP) was conducted in a diverse RA population that included patients with different disease durations and different prior and background treatments for RA including those who were biologic naïve and also those with previous anti-TNF use [5 & ]. At 12 weeks, 51.1% of the certolizumab-treated patients achieved ACR20 compared with 25.9% in the placebo group.
KEY POINTS
Newer formulations of tocilizumab (subcutaneous vs. original intravenous formulation) and golimumab (intravenous vs. original subcutaneous formulation) have shown similar efficacy to their original formulations among patients with rheumatoid arthritis.
Head-to-head clinical trials among biologics for rheumatoid arthritis have not found major differences across biologics when given with background methotrexate.
Current studies on discontinuation of antitumor necrosis factor for rheumatoid arthritis suggest that for patients who had greater depth of treatment benefit (ideally clinically remission) that is more sustained (several months or longer), discontinuation of anti-TNF therapy could be considered.
Extensive studies to determine the impact of tocilizumab and other biologics on cardiovascular disease in patients with rheumatoid arthritis suggest that the numeric increase in lipid molecules may not be harmful as initially posited. Among patients who previously used anti-TNF, the proportions of ACR20 vs. placebo and ACR50 vs. placebo were 47.2 vs. 27.5 and 21.6 vs. 11.3, respectively. These data suggest that even patients who have previously received anti-TNF therapy can achieve a meaningful benefit with CZP, and the magnitude of benefit is comparable to biologicnaïve patients initiating CZP. Additional biologics in the early phase development for RA are shown in Table 1 and include new targets (e.g. IL-17) [6-8], anti S-CSF [9], monoclonal antibody against B-cell activating factor (BAFF) [10, 11] and new methods to block cytokine signaling (e.g. blocking IL-6 itself rather than its receptor) [12, 13] .
COMPARATIVE EFFICACY OF ANTITUMOR NECROSIS FACTOR AND NONANTITUMOR NECROSIS FACTOR BIOLOGICS TO NONBIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND TO EACH OTHER
The Treatment of Early Aggressive RA (TEAR) trial [14 && ] was an investigator-initiated, randomized, blinded study of early RA patients (median disease duration 4 months) that compared MTX, hydroxychloroquine and sulfasalazine in combination (i.e. triple therapy) to combination therapy with etanercept (ETA) plus MTX to MTX monotherapy for 6 months, with mandatory step-up to triple therapy or ETA only if the DAS28 is at least 3.2, resulting in four arms. Clinical outcomes were similar among all treatment groups at the end of 2 years. A statistically significant difference in radiographic progression favoring the ETA treatment arms was found, although it was small in magnitude. Consistent with the TEAR results, the 2-year follow-up of the nonblinded, parallel group Swedish Farmacotherapy (Swefot) trial [15] showed that although anti-TNF-treated patients using infliximab had better radiographic outcomes, there was no difference between triple therapy and infliximab in the clinical outcomes at 18 or 24 months. Likewise, there were no differences between the two treatment arms in utility or quality-adjusted life-years [16] .
A strategy trial [17] evaluated aggressive vs. conventional treatment for early RA patients with only moderately active disease (between two and five swollen joints). The aggressive treatment arm included adalimumab (ADA), whereas conventional treatment was according to the rheumatologist's discretion with nonbiologic DMARDs and without prednisone. Remission rates were 66 and 49% and HAQ decreased by a mean of À0.09 (0.50) and À0.25 (0.59) units (P ¼ 0.06) in the aggressive and conventional care group, respectively. The median SHS increase between 0 and 2 years was 0 [inter-quantile range (IQR) 0-1.0] in the entire aggressive group and 0.25 (IQR 0-2.5) in the entire conventional care group (P ¼ 0.17). The sample size of this study was small (n ¼ 80), which may explain why significant differences were not found although the magnitude of the differences was small (Fig. 2) .
Whereas the aforementioned trials compared biologics with aggressive DMARDs therapy, results from head-to-head clinical trials comparing anti-TNF biologics to one another or to nonanti-TNF biologics are now available. A trial was undertaken in which patients with established active RA despite prior or current use of two DMARDs including MTX and who were biologic naive compared ADA 40 mg every 2 weeks vs. ETA 50 mg weekly, both in combination with MTX. The proportion of good, moderate and nonresponders based on DAS28 at 52 weeks were ] comparing ETA vs. ADA with respect to immunogenicity showed that the overall treatment response was comparable between ETA and ADA-treated patients (adjusted odds ratio [OR] 0.81, 95% CI 0.54-1.21). In a comparison between ETA and patients receiving ADA without anti-ADA antibodies, the OR for achieving better clinical outcome was 0.55, 95% CI (0.37-0.83) (P ¼ 0.004), favoring ADA; when ETA was compared to ADA patients with anti-ADA antibodies, the OR was 2.62 (1.19-5.75) (P ¼ 0.017), favoring ETA. These data suggest that ADA appears to be more effective in patients who do not develop antibodies to the drug and that those who developed anti-ADA antibodies ] of the ATTEST trial showed that changing from infliximab, regardless of clinical response, to ABA provided sustained or increased efficacy after the change in medications according to DAS28. A larger noninferiority trial compared ADA vs. ABA subcutaneous in combination with MTX in MTX-IR patients showed at 1 year, 64.8 and 63.4% of patients demonstrated an ACR20 response; the estimated difference (95% CI) between groups was 1.8 (À5.6, 9.2), demonstrating the noninferiority of ABA vs. ADA. All efficacy measures showed similar results and kinetics of response. Rates of radiographic nonprogression using van der Heijde modified Sharp total scores smallest detectable change (mTSS.SDC) were 84.8 and 88.6%; mean changes from baseline in mTSS of 0.58 and 0.38. Discontinuation because of adverse events was 3.1 vs. 6.1%, because of serious adverse events was 1.3 vs. 3% ABA vs. ADA, respectively [22 && ]. Preliminary results of a trial designed to test the superiority of biologic monotherapy in patients with RA of at least 6-month duration who were MTX intolerant compared TCZ monotherapy to ADA. Results of that study [23] showed more favorable TCZ compared with ADA (change in DAS28 of À3.3 and À1.9, P < 0.001).
ANTITUMOR NECROSIS FACTOR DISCONTINUATION TRIALS
Discontinuation of biologic therapy, particularly anti-TNF therapy, has been suggested as a possibility to consider for patients doing well stopping therapy might maintain LDA or remission off biologic treatment, with or without background therapies like MTX. A prospective cohort studied which factors were associated with successful discontinuation of anti-TNF and found that early combination therapy (MTX plus anti-TNF) within the first 6 months of symptoms of RA [24] was the only clinical predictor identified. Another study conducted among patients who agreed to discontinue ADA as part of routine clinical practice after sustained remission for at least 6 months (DAS28 <2.6) showed that 12 months after discontinuing ADA, 36% of patients remained in remission by DAS28 less than 2.6 and 45% were in remission based upon a simplified disease activity index (SDAI) of 3.3. Additionally, 95% showed no evidence of radiographic progression over that year [25] . A post hoc analysis after 4 years of treatment of the 'Behandel Strategieën' BeST study [26] was published, in which patients who have achieved a DAS44 less than 1.6 discontinued treatment gradually until completely off medication. Between months 24 and 48, 20% of all patients achieved drug-free remission for a mean duration of 9 months. At year 4, 13% achieved drug-free remission with a mean duration of 11 months. Factors associated with drug-free remission were the absence of anticyclic citrullinated peptide (CCP), male sex and shorter RA symptom duration (<6 months). A majority of patients (94%) in whom therapy was withdrawn experienced an increase in disease activity returned to either remission or LDA once the treatment with the last DMARD used (either MTX or sulfasalazine) was reinitiated. Treatment was intensified if DAS44 was greater than 2.4. These patients did not experience any radiographic progression [27] .
Preliminary results for more recent trials that discontinued anti-TNF biologic in early RA patients have been recently published in abstract form. A randomized clinical trial (RCT) comparing ADA vs. MTX monotherapy showed that treatment with ADA plus MTX was significantly superior to MTX monotherapy at 26 weeks with respect to clinical, radiographic and functional outcomes in patients with early active RA who were treatment naïve [28] . A second phase of the same trial with 52-week follow-up [29] identified patients who achieved LDA at two consecutive visits after 6 months of ADA treatment and randomized them to discontinue or continue ADA while continuing MTX. Among those who continued MTX but discontinued ADA, 51% remained in remission by SDAI 3.3 one year later and 84% remained in LDA (SDAI 11). Moreover, only 8% more patients who continued ADA remained in remission (P ¼ 0.07) and 11% more remained in LDA (P ¼ 0.10) compared with those who discontinued ADA, suggesting that many patients in this trial did not need ongoing ADA therapy to continue to do well. In a similarly designed study of ETA, patients had to have achieved LDA or remission at one visit at 6 months before the discontinuation of ETA. Patients who discontinued ETA experienced a significant increase in disease activity compared with those who continued either 50 mg of ETA or a reduced ETA dose of 25 mg weekly [30] . These results suggest that patients needed to have a greater depth of treatment benefit (ideally clinically remission, not just LDA) that is more sustained (not just a single visit) before discontinuation of anti-TNF therapy should be considered. Predictors of remission are not yet available, although a small observational study [31 & ] suggested that lack of power Doppler signal on musculoskeletal ultrasound may be useful to predict successful discontinuation of RA therapy.
CLINICAL TRIALS ON ASSESSMENT OF CARDIOVASCULAR RISK WITH TOCILIZUMAB
Results from RCTs of TCZ, an IL-6 receptor blocker, have raised concerns regarding a possible increase in the risk of CVD, given increased lipid levels observed with the use of this agent [32] . More recent trials have been developed with the objective of clarifying CVD risk with TCZ use. An open-label trial conducted in Japan of biologic and MTX-naïve RA patients with DAS28 greater than 3.2 evaluated the effect of TCZ vs. ETA and ADA monotherapy on arterial stiffness [33 & ]. They measured two different parameters to determine arterial stiffness: cardio-ankle vascular index (CAVI) [34] and the augmentation index corrected to a heart rate of 75 bpm (Aix@75) [35] . Both of these measures are surrogate parameters of arterial stiffness and are commonly used as predictors of CVD risk. At the end of the 24 weeks of follow-up and compared with baseline, TCZ, ETA and ADA all significantly and comparably decreased the CAVI and Aix@75. TCZ increased the fasting total cholesterol levels significantly compared with baseline 18.0 AE 5.2 mg/dl (P ¼ 0.03) and compared with ADA and ETA (P ¼ 0.032 and 0.024, respectively). There were no significant changes with any of the biologics in carotid-intima media thickness and carotid artery plaque.
Another RCT of TCZ evaluated the effects of TCZ on lipid particle size and arterial stiffness by pulse wave velocity [36] . TCZ did not have a statistically significant effect on the concentration of small low-density lipoprotein (LDL) particles, considered pro-atherogenic [37, 38] , at either week 12 [mean difference, 0.0 nmol/l (95% CI À115.0, 115.0)] or week 24 [mean difference, 11.2 nmol/l (95% CI À106.7, 129.1)]. TCZ was associated with a median (IQR) increase in total cholesterol at 12 weeks of 12.6% (À0.05, 23.9); LDL, 10.6% (1.0, 28.9); HDL, 3.1% (À6.6, 12.7) and triglycerides, 28.1% (À1.7, 63.5). Conversely, a substantial decrease (>30%) in lipoprotein (a) [39] , a risk factor known to be associated with vascular events, occurred more frequently in TCZ-treated patients compared with placebo patients. In terms of arterial stiffness, a small significant increase at 12 weeks in favor of placebo was observed, although there was no difference between the treatment groups at 24 weeks.
The data presented in this section suggest that the impact of TCZ on CVD risk is not necessarily detrimental and that the numeric increase in lipid molecules is not as harmful as initially posited, as more specific parameters of CVD risk like arterial stiffness and LDL particle size are either affected in a positive way or negligibly by TCZ.
CONCLUSION
New formulations of existing compounds may provide greater treatment options for the management of RA. At least when used with background MTX, most trials have not identified important differences in the efficacy across the biologics available for RA, although there may be advantages for some when given as monotherapy. Several new trials suggest that a meaningfully large subgroup of RA patients can be withdrawn successfully from anti-TNF biologic treatment. However, further characterization of predictors of successful withdrawal, and requiring a greater and more sustained depth of clinical response before discontinuing, is probably warranted than was studied in most discontinuation trials. Finally, the increases in lipid molecules observed with TCZ and some other biologics (e.g. anti-TNF therapy) do not appear to be detrimental to CVD risk and underscores the need to better understand the complex interactions between systemic inflammation, lipids, and CVD risk and outcomes for patients with RA.
Papers of particular interest, published within the annual period of review, have been highlighted as: & of special interest && of outstanding interest Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 404-405). This study evaluated the efficacy and safety of certolizumab in a diverse RA population including early RA, long-standing RA and a variety of prior RA treatments including other anti-TNFs and DMARDs. This study is relevant, given that the majority of the data in the past have suggested that there is no significant improvement in RA activity by changing between anti-TNF biologics. This study is one of the first, if not the first one, to show some benefit in switching to certolizumab in terms of RA disease activity regardless of the prior treatment. A head-to-head study that compared adalimumab vs. etanercept, but this time with respect to immunogenicity. This one showed no overall major differences between these two biologics. However, when patients were stratified by the presence or not of antiadalimumab antibodies, patients who received adalimumab and did not have antiadalimumab antibodies had better clinical outcome compared with etanercept. Etanercept had better clinical outcome when compared with patients receiving adalimumab with antiadalimumab antibodies. The relevance of these data is that they suggest that some of the efficacy of the monoclonal antibodies might be driven in part by their immunogenicity. Whether some monoclonal antibodies used in the treatment of RA might be more immunogenic than others will need to be evaluated further. 
